{
    "hands_on_practices": [
        {
            "introduction": "This first practice provides a foundational exercise in applying a quantitative grading system to predict prognosis. We will use the French Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) system for soft tissue sarcoma, a clear example of how pathologists translate microscopic features into a standardized score. This exercise will guide you through calculating a tumor's grade and then using that grade in a logistic model to estimate a clinically vital outcome: the probability of metastasis .",
            "id": "4810281",
            "problem": "A resected soft tissue sarcoma is graded using the French Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) system, which assigns three component scores: differentiation $D \\in \\{1,2,3\\}$, mitotic count $M \\in \\{1,2,3\\}$, and tumor necrosis $N \\in \\{0,1,2\\}$. The total score is $S = D + M + N$. By established FNCLCC definitions, grade $G$ is determined from $S$ as follows: if $S \\in \\{2,3\\}$ then $G=1$; if $S \\in \\{4,5\\}$ then $G=2$; if $S \\in \\{6,7,8\\}$ then $G=3$. To estimate the $5$-year probability of distant metastasis, consider a logistic model commonly used for binary clinical outcomes: the linear predictor is $z = \\alpha + \\beta S$ and the probability is $p = \\frac{1}{1+\\exp(-z)}$. For this cohort, suppose $\\alpha = -4$ and $\\beta = 0.5$. Given differentiation $D=3$, necrosis $N=2$, and mitoses $M=2$, compute the FNCLCC grade $G$ and the metastasis probability $p$. Express the probability $p$ as a decimal fraction and round it to four significant figures.",
            "solution": "The user has provided a problem that requires the calculation of a tumor grade and a probability of metastasis based on a specific clinical grading system and a statistical model.\n\n### Step 1: Problem Validation\n\n**1.1. Extraction of Givens**\n-   Grading system: French Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC).\n-   Component scores:\n    -   Differentiation $D \\in \\{1, 2, 3\\}$.\n    -   Mitotic count $M \\in \\{1, 2, 3\\}$.\n    -   Tumor necrosis $N \\in \\{0, 1, 2\\}$.\n-   Total score formula: $S = D + M + N$.\n-   Grading rule:\n    -   Grade $G=1$ if $S \\in \\{2, 3\\}$.\n    -   Grade $G=2$ if $S \\in \\{4, 5\\}$.\n    -   Grade $G=3$ if $S \\in \\{6, 7, 8\\}$.\n-   Logistic model for metastasis probability $p$:\n    -   Linear predictor: $z = \\alpha + \\beta S$.\n    -   Probability formula: $p = \\frac{1}{1+\\exp(-z)}$.\n-   Model parameters: $\\alpha = -4$, $\\beta = 0.5$.\n-   Patient-specific scores: $D = 3$, $M = 2$, $N = 2$.\n-   Output requirements: Compute the FNCLCC grade $G$ and the metastasis probability $p$, with $p$ rounded to four significant figures.\n\n**1.2. Validation Using Extracted Givens**\n-   **Scientific Grounding**: The problem is grounded in established medical practice. The FNCLCC system is a standard method for grading soft tissue sarcomas. Logistic regression is a fundamental and widely used statistical technique for modeling binary outcomes in epidemiology and clinical research. The problem is scientifically sound.\n-   **Well-Posedness**: The problem is well-posed. All necessary inputs ($D, M, N, \\alpha, \\beta$), definitions (formulas for $S, G, z, p$), and conditions are explicitly provided. The values given for $D, M, N$ are within their allowed ranges. The instructions for the output format are clear. A unique solution can be deterministically calculated.\n-   **Objectivity**: The problem is stated in precise, objective language, free of ambiguity or subjective claims.\n\n**1.3. Verdict and Action**\nThe problem is valid. It is scientifically grounded, well-posed, and objective. There are no identifiable flaws. I will proceed with the solution.\n\n### Step 2: Solution Derivation\n\nThe problem requires two calculations: the FNCLCC grade $G$ and the $5$-year probability of distant metastasis $p$.\n\n**2.1. Calculation of the Total Score (S)**\nThe total score $S$ is the sum of the three component scores: differentiation ($D$), mitotic count ($M$), and tumor necrosis ($N$).\nThe formula is given as:\n$$S = D + M + N$$\nSubstituting the provided values $D=3$, $M=2$, and $N=2$:\n$$S = 3 + 2 + 2 = 7$$\n\n**2.2. Determination of the FNCLCC Grade (G)**\nThe grade $G$ is determined by the value of the total score $S$ according to the rules provided:\n-   If $S \\in \\{2,3\\}$, then $G=1$.\n-   If $S \\in \\{4,5\\}$, then $G=2$.\n-   If $S \\in \\{6,7,8\\}$, then $G=3$.\n\nOur calculated total score is $S=7$. Since $7$ is in the set $\\{6, 7, 8\\}$, the corresponding grade is:\n$$G = 3$$\n\n**2.3. Calculation of the Metastasis Probability (p)**\nThe probability $p$ is calculated using a logistic regression model. First, we compute the linear predictor $z$, and then we use $z$ to find $p$.\n\n**2.3.1. Compute the Linear Predictor (z)**\nThe formula for the linear predictor is:\n$$z = \\alpha + \\beta S$$\nThe given parameters are $\\alpha = -4$ and $\\beta = 0.5$. We use our calculated total score $S=7$.\n$$z = -4 + (0.5)(7) = -4 + 3.5 = -0.5$$\n\n**2.3.2. Compute the Probability (p)**\nThe logistic function gives the probability $p$ as:\n$$p = \\frac{1}{1 + \\exp(-z)}$$\nSubstituting the value $z = -0.5$:\n$$p = \\frac{1}{1 + \\exp(-(-0.5))} = \\frac{1}{1 + \\exp(0.5)}$$\nTo obtain the final numerical answer, we calculate the value and round it to four significant figures as requested.\n$$p \\approx \\frac{1}{1 + 1.64872127} = \\frac{1}{2.64872127} \\approx 0.37754066...$$\nRounding this value to four significant figures gives:\n$$p \\approx 0.3775$$\n\nThe two required values are the grade $G=3$ and the probability $p \\approx 0.3775$.",
            "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n3 & 0.3775\n\\end{pmatrix}\n}\n$$"
        },
        {
            "introduction": "Building on the fundamentals of grading, this practice introduces the more complex Gleason system used for prostate adenocarcinoma. Unlike a simple sum, the Gleason score depends on the primary and secondary architectural patterns, and modern prognostic models can even incorporate minor high-grade components. This exercise demonstrates how sophisticated grading systems and nomograms integrate multiple pathological features to provide a more refined, patient-specific prognosis .",
            "id": "4810298",
            "problem": "Adenocarcinoma of the prostate is graded by the Gleason system, which assigns a primary architectural pattern and a secondary architectural pattern, each on a scale from $3$ to $5$, and sums them to yield the Gleason score. The International Society of Urological Pathology (ISUP) Grade Group system collapses Gleason scores into five ordered categories (Grade Group $1$ through Grade Group $5$) based on well-established mappings. Minor high-grade components (historically termed “tertiary” patterns) of pattern $5$ occupying a small fraction of the tumor are recorded and may inform risk, but do not change the Gleason score or the ISUP Grade Group when they are minor.\n\nConsider a patient whose tumor shows primary pattern $4$, secondary pattern $3$, and a minor pattern $5$ component occupying a fraction $r=0.05$ of the tumor volume. Using core definitions:\n\n- Gleason score is the sum of the primary and secondary patterns.\n- ISUP Grade Group mapping is: Grade Group $1$ for Gleason $3+3=6$, Grade Group $2$ for Gleason $3+4=7$, Grade Group $3$ for Gleason $4+3=7$, Grade Group $4$ for Gleason $8$ (which includes $4+4$, $3+5$, and $5+3$), and Grade Group $5$ for Gleason $9$ to $10$.\n\nTo estimate the $5$-year probability of disease progression after definitive therapy, a calibrated nomogram uses a logistic model grounded in the odds–probability relationship. Let $g$ denote the ISUP Grade Group, and let the linear predictor be\n$$\n\\text{LP}=\\beta_{0}+\\beta_{G}\\,g+\\beta_{r}\\,r,\n$$\nwith coefficients obtained from calibration on an external cohort: $\\beta_{0}=-1.90$, $\\beta_{G}=0.33$, and $\\beta_{r}=4.00$. The progression probability $p$ is then given by the logistic transformation\n$$\np=\\frac{1}{1+\\exp\\!\\big(-\\text{LP}\\big)}.\n$$\n\nTasks:\n1. Assign the Gleason score from the primary and secondary patterns.\n2. Assign the ISUP Grade Group from the Gleason score definition above.\n3. Compute the $5$-year progression probability $p$ using the calibrated nomogram. Round the probability to four significant figures and express it as a decimal (no percentage sign).\n\nProvide your final answer as a row matrix with three entries in the order: Gleason score, ISUP Grade Group, progression probability $p$.",
            "solution": "The problem statement will first be validated for scientific soundness, completeness, and objectivity.\n\n### Step 1: Extract Givens\n- The Gleason system assigns a primary and secondary architectural pattern, each on a scale from $3$ to $5$.\n- The Gleason score is the sum of the primary and secondary patterns.\n- Minor high-grade components (termed \"tertiary\" patterns) do not change the Gleason score or the ISUP Grade Group when they are minor.\n- Patient-specific data:\n  - Primary pattern: $4$.\n  - Secondary pattern: $3$.\n  - Minor pattern $5$ component fraction: $r=0.05$.\n- ISUP Grade Group mapping rules:\n  - Grade Group $1$: Gleason score $3+3=6$.\n  - Grade Group $2$: Gleason score $3+4=7$.\n  - Grade Group $3$: Gleason score $4+3=7$.\n  - Grade Group $4$: Gleason score $8$.\n  - Grade Group $5$: Gleason score $9$ to $10$.\n- A logistic model is used to estimate the $5$-year probability of disease progression, $p$.\n- The linear predictor is $\\text{LP}=\\beta_{0}+\\beta_{G}\\,g+\\beta_{r}\\,r$, where $g$ is the ISUP Grade Group.\n- Model coefficients: $\\beta_{0}=-1.90$, $\\beta_{G}=0.33$, $\\beta_{r}=4.00$.\n- The progression probability is given by $p=\\frac{1}{1+\\exp(-\\text{LP})}$.\n- The required output is a set of three values: the Gleason score, the ISUP Grade Group, and the progression probability $p$ rounded to four significant figures.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is evaluated against the validation criteria.\n- **Scientifically Grounded**: The problem is grounded in established principles of urologic pathology and biostatistics. The Gleason scoring system, the ISUP 2014/WHO 2016 Grade Group system, and the use of prognostic logistic regression models (nomograms) are standard clinical and research tools in oncology. The definitions and mappings are accurate.\n- **Well-Posed**: All necessary data, definitions, and equations are provided to determine the three required values. The instructions are unambiguous. A unique, stable, and meaningful solution exists.\n- **Objective**: The problem is stated in precise, formal language, free of subjectivity or opinion.\n\n### Step 3: Verdict and Action\nThe problem is deemed **valid**. It is scientifically sound, well-posed, and objective. The solution process may proceed.\n\n### Solution\n\nThe solution requires a three-step calculation based on the provided definitions and formulas.\n\n**Part 1: Assign the Gleason score**\n\nThe Gleason score is defined as the sum of the primary and secondary architectural patterns. The problem explicitly states that the presence of a minor, or \"tertiary\", pattern does not alter the Gleason score.\nGiven:\n- Primary pattern $= 4$\n- Secondary pattern $= 3$\n\nThe Gleason score is the sum of these two patterns.\n$$ \\text{Gleason Score} = \\text{Primary Pattern} + \\text{Secondary Pattern} = 4 + 3 = 7 $$\n\n**Part 2: Assign the ISUP Grade Group**\n\nThe ISUP Grade Group ($g$) is determined from the Gleason score, critically including the specific primary and secondary components. The problem provides the mapping rules. The patient's Gleason score is $7$, which was derived from a primary pattern of $4$ and a secondary pattern of $3$. This is denoted as Gleason score $4+3=7$.\n\nAccording to the provided ISUP Grade Group mapping:\n- Grade Group $1$: Gleason $3+3=6$\n- Grade Group $2$: Gleason $3+4=7$\n- Grade Group $3$: Gleason $4+3=7$\n- Grade Group $4$: Gleason $8$\n- Grade Group $5$: Gleason $9-10$\n\nThe patient's score of $4+3=7$ falls into the category of ISUP Grade Group $3$. Therefore, $g=3$.\n\n**Part 3: Compute the 5-year progression probability $p$**\n\nThe progression probability, $p$, is calculated using the provided logistic regression model. First, we compute the linear predictor, $\\text{LP}$.\n\nThe formula for the linear predictor is:\n$$ \\text{LP} = \\beta_{0} + \\beta_{G}\\,g + \\beta_{r}\\,r $$\nThe values for the parameters are:\n- $\\beta_{0} = -1.90$\n- $\\beta_{G} = 0.33$\n- $\\beta_{r} = 4.00$\n- $g = 3$ (from Part 2)\n- $r = 0.05$ (given)\n\nSubstituting these values into the equation for $\\text{LP}$:\n$$ \\text{LP} = -1.90 + (0.33)(3) + (4.00)(0.05) $$\n$$ \\text{LP} = -1.90 + 0.99 + 0.20 $$\n$$ \\text{LP} = -1.90 + 1.19 $$\n$$ \\text{LP} = -0.71 $$\n\nNext, we compute the probability $p$ using the logistic function:\n$$ p = \\frac{1}{1 + \\exp(-\\text{LP})} $$\nSubstituting the calculated value of $\\text{LP}$:\n$$ p = \\frac{1}{1 + \\exp(-(-0.71))} $$\n$$ p = \\frac{1}{1 + \\exp(0.71)} $$\n\nNow, we calculate the numerical value of $p$ and round it to four significant figures.\n$$ \\exp(0.71) \\approx 2.0339908 $$\n$$ p \\approx \\frac{1}{1 + 2.0339908} = \\frac{1}{3.0339908} \\approx 0.3296020 $$\n\nRounding to four significant figures gives:\n$$ p \\approx 0.3296 $$\n\nThe three required values are the Gleason score, the ISUP Grade Group, and the progression probability $p$.\n- Gleason score: $7$\n- ISUP Grade Group: $3$\n- Progression probability $p$: $0.3296$\n\nThese are presented in a row matrix as requested.",
            "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n7 & 3 & 0.3296\n\\end{pmatrix}\n}\n$$"
        },
        {
            "introduction": "Our final practice shifts from calculation to clinical reasoning, focusing on how grade and stage are synthesized to guide treatment. This exercise explores the critical concept of \"grade-stage discordance,\" which occurs when a tumor's biological aggressiveness (high grade) conflicts with its anatomical spread (low stage), or vice versa. Understanding how to manage these discordant cases is essential for appreciating the sophisticated, individualized nature of modern cancer care .",
            "id": "4810325",
            "problem": "An oncologist must decide adjuvant therapy for several newly diagnosed cancers. The core framework is that histologic grade estimates intrinsic biological aggressiveness (based on differentiation, nuclear atypia, and proliferative activity), whereas anatomic stage categorizes extent of spread using the Tumor Node Metastasis (TNM) system. By widely accepted convention, grade and stage predict different but complementary risks: grade correlates with the likelihood of rapid growth and early recurrence given a fixed tumor burden, while stage correlates with tumor burden and the probability that disease control requires systemic or extensive regional therapy. Grade–stage discordance refers to a mismatch in these axes, such that a tumor is low stage but high grade, or high stage but low grade. From these fundamentals, identify which of the following statements correctly characterize grade–stage discordance and its management implications.\n\nA. A papillary urothelial carcinoma confined to the mucosa (stage $Ta$) but reported as high grade has a high risk of progression; intravesical Bacillus Calmette–Guérin (BCG) immunotherapy or even early cystectomy may be indicated despite low stage. This is an example where low stage but high grade drives management.\n\nB. A well-differentiated small-intestinal neuroendocrine tumor with multiple liver metastases (stage $IV$) and a low proliferation index is biologically indolent by grade but requires systemic or liver-directed therapy because anatomic stage is advanced; here high stage but low grade drives management decisions.\n\nC. Grade–stage discordance indicates misclassification; when assessment is accurate, grade and stage should align, and treatment should follow stage exclusively.\n\nD. In ductal carcinoma in situ of the breast, high nuclear grade automatically upgrades the TNM $T$ category to invasive disease; therefore, high-grade in situ carcinoma should be staged and treated as invasive carcinoma.\n\nE. A prostate adenocarcinoma clinically confined to the gland ($T2N0M0$) with a Gleason score of $9$ (International Society of Urological Pathology (ISUP) grade group $5$) may warrant multimodal therapy (for example, radiation plus androgen-deprivation therapy) despite low anatomic stage; this illustrates low stage but high grade guiding management.\n\nSelect all that apply.",
            "solution": "The user wants me to validate and solve a problem in pathophysiology regarding neoplasm classification.\n\n**Step 1: Extract Givens**\n\nThe problem statement provides the following definitions and principles:\n1.  **Histologic grade:** Estimates intrinsic biological aggressiveness, based on differentiation, nuclear atypia, and proliferative activity.\n2.  **Anatomic stage:** Categorizes extent of spread using the Tumor Node Metastasis ($TNM$) system.\n3.  **Grade vs. Stage Function:** Grade correlates with the likelihood of rapid growth and early recurrence for a given tumor burden. Stage correlates with tumor burden and the probability that disease control requires systemic or extensive regional therapy. They predict different but complementary risks.\n4.  **Grade–Stage Discordance:** A mismatch where a tumor is low stage but high grade, or high stage but low grade.\n5.  **Question:** Identify the statement(s) that correctly characterize grade–stage discordance and its management implications.\n\n**Step 2: Validate Using Extracted Givens**\n\n1.  **Scientific Groundedness:** The problem is firmly grounded in the fundamental principles of clinical oncology and pathology. The definitions of histologic grade and anatomic stage ($TNM$) are accurate and standard. The concept that grade (biology) and stage (anatomy) are distinct but complementary prognostic factors is a cornerstone of cancer management. Grade-stage discordance is a well-recognized clinical phenomenon that drives many treatment decisions. The premises are scientifically sound.\n2.  **Well-Posed:** The problem is well-posed. It provides a clear conceptual framework and asks for an evaluation of specific clinical scenarios against this framework. A unique and correct set of answers can be determined by applying established oncologic principles.\n3.  **Objectivity:** The language is objective and clinical. It uses standard, precisely defined terminology.\n4.  **Completeness:** The provided definitions are sufficient to evaluate the options. No essential information is missing.\n5.  **Realism:** The scenarios described are realistic and frequently encountered in clinical practice.\n6.  **Other Flaws:** The problem is not ill-posed, ambiguous, trivial, or based on faulty logic.\n\n**Step 3: Verdict and Action**\n\nThe problem statement is **valid**. It is scientifically correct, logically consistent, and well-posed. I will proceed to derive the solution and evaluate each option.\n\n**Solution Derivation**\n\nThe core principle is that both tumor grade (aggressiveness) and stage (spread) must be considered together to determine prognosis and treatment. In cases of discordance, the \"worse\" factor (i.e., high grade or high stage) often disproportionately influences the management plan, pushing it toward more aggressive therapy than the \"better\" factor would suggest alone.\n\n**Option-by-Option Analysis**\n\n**A. A papillary urothelial carcinoma confined to the mucosa (stage $Ta$) but reported as high grade has a high risk of progression; intravesical Bacillus Calmette–Guérin (BCG) immunotherapy or even early cystectomy may be indicated despite low stage. This is an example where low stage but high grade drives management.**\n\n*   **Analysis:** A stage $Ta$ tumor is non-invasive and confined to the urothelial lining, representing the lowest stage for bladder cancer. This is \"low stage.\" However, being \"high grade\" indicates high biological aggressiveness, a high mitotic rate, and significant nuclear pleomorphism. This histologic feature imparts a high risk of recurrence and, critically, progression to muscle-invasive disease, which has a much worse prognosis. Therefore, despite the low anatomic stage, the high grade is a major driver of clinical concern. Standard treatment guidelines for high-risk non-muscle-invasive bladder cancer (which includes high-grade $Ta$) recommend adjuvant intravesical therapy with BCG to reduce the risk of progression. In very high-risk cases, early radical cystectomy is also a valid consideration. This statement accurately portrays a classic scenario of low-stage, high-grade discordance where the high grade dictates a more aggressive therapeutic approach.\n*   **Verdict:** Correct.\n\n**B. A well-differentiated small-intestinal neuroendocrine tumor with multiple liver metastases (stage $IV$) and a low proliferation index is biologically indolent by grade but requires systemic or liver-directed therapy because anatomic stage is advanced; here high stage but low grade drives management decisions.**\n\n*   **Analysis:** A \"well-differentiated\" tumor with a \"low proliferation index\" (e.g., low Ki-67 index) is, by definition, a low-grade neuroendocrine tumor (NET G1). It is biologically indolent, meaning slow-growing. This is \"low grade.\" However, the presence of \"multiple liver metastases\" means the disease is widely disseminated and corresponds to stage $IV$ disease. This is \"high stage.\" This is a classic example of high-stage, low-grade discordance. While the tumor's biology is indolent, its anatomical extent (stage $IV$) makes it incurable by local measures alone and threatens long-term organ function and survival. Management is therefore driven by the advanced stage, requiring systemic therapies (like somatostatin analogs or targeted agents) or aggressive regional treatments (like liver-directed therapies) to control the disease burden. The statement correctly identifies this dynamic.\n*   **Verdict:** Correct.\n\n**C. Grade–stage discordance indicates misclassification; when assessment is accurate, grade and stage should align, and treatment should follow stage exclusively.**\n\n*   **Analysis:** This statement is fundamentally incorrect. It contradicts the premise of the question and the reality of oncology. Grade and stage measure orthogonal aspects of a tumor: biology vs. anatomy. There is no biological law that requires them to be correlated. An aggressive cancer can be caught early (high grade, low stage), and a slow-growing cancer can be discovered late after it has spread (low grade, high stage). Grade–stage discordance is a true biological and clinical phenomenon, not an error in classification. Furthermore, the claim that treatment should follow stage exclusively is a dangerous oversimplification. As demonstrated in options A and E, grade is a critical determinant of treatment, especially in localized disease.\n*   **Verdict:** Incorrect.\n\n**D. In ductal carcinoma in situ of the breast, high nuclear grade automatically upgrades the TNM $T$ category to invasive disease; therefore, high-grade in situ carcinoma should be staged and treated as invasive carcinoma.**\n\n*   **Analysis:** This statement is factually wrong regarding cancer staging rules. Ductal carcinoma *in situ* (DCIS) is, by definition, a pre-invasive or non-invasive lesion. In the $TNM$ system, it is designated as $Tis$. Histologic grade (low, intermediate, or high) is a crucial prognostic factor for $DCIS$ that influences the risk of recurrence and decisions about adjuvant radiation therapy, but it **does not** alter the $T$ category. A high-grade $Tis$ lesion remains a $Tis$ lesion; it is not \"upgraded\" to a $T1$ (invasive) stage. It is staged and treated as an in situ carcinoma (Stage 0), not as an invasive carcinoma. The management, while influenced by grade, is distinct from that of invasive cancer (e.g., systemic chemotherapy is not standard for pure $DCIS$).\n*   **Verdict:** Incorrect.\n\n**E. A prostate adenocarcinoma clinically confined to the gland ($T2N0M0$) with a Gleason score of $9$ (International Society of Urological Pathology (ISUP) grade group $5$) may warrant multimodal therapy (for example, radiation plus androgen-deprivation therapy) despite low anatomic stage; this illustrates low stage but high grade guiding management.**\n\n*   **Analysis:** A $T2N0M0$ prostate cancer is anatomically confined to the prostate gland, which represents a \"low anatomic stage\" (localized disease). A Gleason score of $9$ (ISUP Grade Group $5$) is the highest and most aggressive grade, indicating a very high risk of progression and metastatic spread, even if not yet clinically apparent. This is a classic \"low stage, high grade\" discordance. For such a high-risk tumor, single-modality therapy (e.g., surgery alone or radiation alone) is often insufficient. Clinical guidelines strongly recommend multimodal therapy, such as combining external beam radiation with long-term androgen-deprivation therapy (ADT), to address both the local tumor and the high risk of micrometastatic disease. Thus, the extremely high grade is the dominant factor driving the decision for intensive, combined-modality treatment. The statement is a correct characterization of this clinical scenario.\n*   **Verdict:** Correct.",
            "answer": "$$\\boxed{ABE}$$"
        }
    ]
}